文献速递类风湿关节炎

类风湿关节炎患者对智能手机ePRO应用的依从性

Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

研究开发了类风湿关节炎(RA)每日电子患者报告结局(ePRO)智能手机应用,并在随机对照试验中分析接受应用患者的6个月依从性。

要点

  • RA患者对每日ePRO智能手机应用的中位依从率为79%。
  • 年龄≥65岁与基线低疾病活动度是依从性增加的显著预测因素。
  • 该应用在6个月研究期间显示出较强的患者依从性。

核心结论

  • 针对RA开发的ePRO智能手机应用在6个月研究期间患者依从性较强。
  • 年龄≥65岁和基线低疾病活动度与更高的依从性相关。

研究设计与样本

  • 开发RA App v.1.0每日评估应用,作为随机对照试验的一部分进行测试。

主要发现

  • 基线临床疾病活动指数(CDAI)平均为9.7(低疾病活动度)。
  • 每日问题中位依从率为79%(四分位距48-90%)。
  • 年龄≥65岁(P=0.03)和基线低CDAI(P=0.02)是依从性增加的显著预测因素。

临床怎么用

  • RA诊疗中可考虑使用每日ePRO智能手机应用收集患者报告结局。
  • 对年龄≥65岁或基线低疾病活动度患者,应用依从性可能更高。

局限性

  • 研究在美国单一学术风湿病实践开展,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Electronic patient-reported outcomes (ePROs) transmitted digitally allow patients to communicate with their clinicians and track the activity of chronic diseases, such as RA. Several ePRO smartphone apps have been developed in rheumatology, yet few data have been reported regarding patient adherence. We developed a PRO app for RA and assessed adherence over 6 months. METHODS: We developed an app to deliver daily assessments to participants (RA App v.1.0). The app was tested as part of a randomized controlled trial examining potential clinical benefits. The current analyses focus on the adherence to the ePRO app for patients randomized to receive the app. We recruited RA patients from an academic rheumatology practice in the USA. Patients randomized to receive the app received daily notifications regarding ePROs. We examined adherence to the PRO questionnaires over the 6-month study and examined factors related to adherence. RESULTS: Seventy-eight patients received the app and have data included in these analyses: 63 (80.7%) were female, mean age was 55.2 years, 71% had attended college or beyond, and the mean Clinical Disease Activity Index at baseline was 9.7 (low disease activity). Median adherence to the daily questions was 79% (interquartile range 48-90%). Significant predictors of increased adherence were age ≥65 (P = 0.03) and low baseline Clinical Disease Activity Index (P = 0.02). CONCLUSION: We developed and tested an ePRO app for RA over a 6-month study. Adherence to the app was strong. There was correlation between older age and better disease control and increased adherence. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov/, NCT02822521.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Colls J, Lee YC, Xu C, et al. Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2021. PMID: 32572490. doi:10.1093/rheumatology/keaa202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。